Type
miREIA – miRNA enzyme immunoassay
Applications
Whole blood, PBMC
Sample Requirements
10 µl/well
Shipping
At ambient temperature. Upon receipt, store the product at the temperature recommended below.
Storage/Expiration
Store the complete kit at 2 – 8 °C. Under these conditions, all components are stable until the expiration date (see label on the box).
Calibration Curve
Calibration Range
12.5 – 0.39 amol/μl
Limit of Detection
0.13 amol/μl
Intra-assay (Within-Run)
n = 8,
CV = 6.0%
Inter-assay (Run-to-Run)
n = 5,
CV = 7.1%
Spiking Recovery
101.4%
Dilution Linearity
112.9%
Features
- It is intended for research use only
- The total assay time is less than 2.5 hours
- The kit measures hsa-miR-1-3p isolated from human blood
- Assay format is 96 wells
- Standard is synthetic miRNA-based
- Components of the kit are provided ready to use, concentrated or dried
Research topic
Cardiovascular disease, Oncology
Summary
MicroRNAs (miRNAs) are small non-coding RNA molecules, approximately 22 nucleotides in length, that regulate gene translation through silencing or degradation of target mRNAs. They are involved in multiple biological processes, including differentiation and proliferation, metabolism, hemostasis, apoptosis or inflammation, and in pathophysiology of many diseases. Numerous studies have suggested circulating miRNAs as promising diagnostic and prognostic biomarkers of many diseases.
In humans, there are two distinct precursors of mature miR-1-3p, named miR-1-1 and miR-1-2. Genes for miR-1-1 and miR-1-2 precursors are located on chromosomes 20 a 18.
Mature miR-1-3p has pivotal roles in development and physiology of muscle tissues including the heart. Changes in miR-1-3p expression lead to occurrence of many cardiac diseases. miR-1-3p is known to be involved in heart diseases such as hypertrophy, myocardial infarction, and arrhythmias. Studies have shown that miR-1-3p is an important regulator of heart adaption after ischemia or ischemic stress. Under physiological conditions, miR-1-3p is present at very low levels in plasma. However, the level of miR-1-3p is significantly increased in myocardial infarction patients.
In addition to the pathophysiological roles of miR-1-3p in cardiac diseases, many studies have also demonstrated that aberrant expression of miR-1 plays important roles in the initiation, development and metastasis of human cancers such as rhabdomyosarcoma, lung cancer, bladder cancer or prostate cancer.
